The Impact of Genomic Profiling for Novel Cancer Therapy – Recent Progress in Non-Small Cell Lung Cancer

Jingwu Xie; Xiaoli Zhang

doi:10.1016/j.jgg.2015.09.003

Volume 43 Issue 1

Jan. 2016

Turn off MathJax

Article Contents

Article Navigation > Journal of Genetics and Genomics > 2016 > 43(1): 3-10

PDF( 860 KB)

The Impact of Genomic Profiling for Novel Cancer Therapy – Recent Progress in Non-Small Cell Lung Cancer

doi: 10.1016/j.jgg.2015.09.003

Jingwu Xie^{a, b, c, d},
Xiaoli Zhang^{a, b, c, d}

a
Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USA
b
Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
c
Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
d
The Simon Cancer Center and The Wells Center for Pediatrics Research, Indiana University School of Medicine, Indianapolis, IN 46202, USA

More Information

Corresponding author: E-mail address: jinxie@iu.edu (Jingwu Xie)
Received Date: 2015-06-14
Accepted Date: 2015-09-07
Rev Recd Date: 2015-09-02

Available Online: 2015-09-15

Publish Date: 2016-01-20

Abstract

Abstract

There is high expectation for significant improvements in cancer patient care after completion of the human genome project in 2003. Through pains-taking analyses of genomic profiles in cancer patients, a number of targetable gene alterations have been discovered, with some leading to novel therapies, such as activating mutations of EGFR, BRAF and ALK gene fusions. As a result, clinical management of cancer through targeted therapy has finally become a reality for a subset of cancers, such as lung adenocarcinomas and melanomas. In this review, we summarize how gene mutation discovery leads to new treatment strategies using non-small cell lung cancer (NSCLC) as an example. We also discuss possible future implications of cancer genome analyses.
- Targeted therapy,
- Lung cancer,
- Gene mutation

FullText(HTML)

References(64)

References

[1]	Akbay, E.A., Koyama, S., Carretero, J. et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors Cancer Discov., 3 (2013),pp. 1355-1363
[2]	Cancer Genome Atlas Research Network Comprehensive molecular profiling of lung adenocarcinoma Nature, 511 (2014),pp. 543-550
[3]	Carvajal, R.D., Antonescu, C.R., Wolchok, J.D. et al. KIT as a therapeutic target in metastatic melanoma JAMA, 305 (2011),pp. 2327-2334
[4]	Chapman, P.B., Hauschild, A., Robert, C. et al. N. Engl. J. Med., 364 (2011),pp. 2507-2516
[5]	Cooper, W.A., Lam, D.C., O'Toole, S.A. et al. Molecular biology of lung cancer J. Thorac. Dis., 5 (2013),pp. S479-S490
[6]	Couraud, S., Zalcman, G., Milleron, B. et al. Lung cancer in never smokers–a review Eur. J. Cancer, 48 (2012),pp. 1299-1311
[7]	Crystal, A.S., Shaw, A.T., Sequist, L.V. et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer Science, 346 (2014),pp. 1480-1486
[8]	Demetri, G.D., von Mehren, M., Blanke, C.D. et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N. Engl. J. Med., 347 (2002),pp. 472-480
[9]	Druker, B.J., Sawyers, C.L., Kantarjian, H. et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome N. Engl. J. Med., 344 (2001),pp. 1038-1042
[10]	Druker, B.J., Talpaz, M., Resta, D.J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N. Engl. J. Med., 344 (2001),pp. 1031-1037
[11]	Ercan, D., Xu, C., Yanagita, M. et al. Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors Cancer Discov., 2 (2012),pp. 934-947
[12]	Falchook, G.S., Long, G.V., Kurzrock, R. et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial Lancet, 379 (2012),pp. 1893-1901
[13]	Finlay, M.R., Anderton, M., Ashton, S. et al. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor J. Med. Chem., 57 (2014),pp. 8249-8267
[14]	Flaherty, K.T., Infante, J.R., Daud, A. et al. N. Engl. J. Med., 367 (2012),pp. 1694-1703
[15]	Flaherty, K.T., Robert, C., Hersey, P. et al. N. Engl. J. Med., 367 (2012),pp. 107-114
[16]	Foundation, L
[17]	Friboulet, L., Li, N., Katayama, R. et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer Cancer Discov., 4 (2014),pp. 662-673
[18]	Fukuoka, M., Yano, S., Giaccone, G. et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected] J. Clin. Oncol., 21 (2003),pp. 2237-2246
[19]	Gainor, J.F., Tan, D.S., De Pas, T. et al. Progression-free and overall survival in ALK-positive NSCLC patients treated with sequential crizotinib and ceritinib Clin. Cancer Res., 21 (2015),pp. 2745-2752
[20]	Gautschi, O., Zander, T., Keller, F.A. et al. A patient with lung adenocarcinoma and RET fusion treated with vandetanib J. Thorac. Oncol., 8 (2013),pp. e43-44
[21]	Guo, J., Si, L., Kong, Y. et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification J. Clin. Oncol., 29 (2011),pp. 2904-2909
[22]	Heppt, M.V., Tietze, J.K., Graf, S.A. et al. Combination therapy of melanoma using kinase inhibitors Curr. Opin. Oncol., 27 (2015),pp. 134-140
[23]	Janne, P.A., Yang, J.C., Kim, D.W. et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer N. Engl. J. Med., 372 (2015),pp. 1689-1699
[24]	Jin, M., Inoue, S., Umemura, T. et al. Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II Lung Cancer, 34 (2001),pp. 207-218
[25]	Katayama, R., Friboulet, L., Koike, S. et al. Clin. Cancer Res., 20 (2014),pp. 5686-5696
[26]	Khoo, K.H., Verma, C.S., Lane, D.P. Drugging the p53 pathway: understanding the route to clinical efficacy Nat. Rev. Drug Discov., 13 (2014),pp. 217-236
[27]	Kim, D.H., Nelson, H.H., Wiencke, J.K. et al. p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer Cancer Res., 61 (2001),pp. 3419-3424
[28]	Kris, M.G., Johnson, B.E., Berry, L.D. et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs JAMA, 311 (2014),pp. 1998-2006
[29]	Lane, D.P. Cancer. p53, guardian of the genome Nature, 358 (1992),pp. 15-16
[30]	Larkin, J., Ascierto, P.A., Dreno, B. et al. N. Engl. J. Med., 371 (2014),pp. 1867-1876
[31]	Leighl, N.B., Rekhtman, N., Biermann, W.A. et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline J. Clin. Oncol., 32 (2014),pp. 3673-3679
[32]	, Sidransky, D. J. Clin. Oncol., 16 (1998),pp. 1197-1206
[33]	Liu, Y., Marks, K., Cowley, G.S. et al. Cancer Discov., 3 (2013),pp. 870-879
[34]	Long, G.V., Stroyakovskiy, D., Gogas, H. et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma N. Engl. J. Med., 371 (2014),pp. 1877-1888
[35]	Lynch, T.J., Bell, D.W., Sordella, R. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N. Engl. J. Med., 350 (2004),pp. 2129-2139
[36]	Mukhopadhyay, S., Pennell, N.A., Ali, S.M. et al. RET-rearranged lung adenocarcinomas with lymphangitic spread, psammoma bodies, and clinical responses to cabozantinib J. Thorac. Oncol., 9 (2014),pp. 1714-1719
[37]	Ng, C.S., Zhang, J., Wan, S. et al. Tumor p16M is a possible marker of advanced stage in non-small cell lung cancer J. Surg. Oncol., 79 (2002),pp. 101-106
[38]	Otterson, G.A., Kratzke, R.A., Coxon, A. et al. Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB Oncogene, 9 (1994),pp. 3375-3378
[39]	Paez, J.G., Janne, P.A., Lee, J.C. et al. Science, 304 (2004),pp. 1497-1500
[40]	Piotrowska, Z., Niederst, M.J., Karlovich, C.A. et al. Heterogeneity underlies the emergence of EGFR T790 wild-type clones following treatment of T790M-oositive cancers with a third generation EGFR Inhibitor Cancer Discov., 5 (2015),pp. 713-722
[41]	Poulikakos, P.I., Persaud, Y., Janakiraman, M. et al. Nature, 480 (2011),pp. 387-390
[42]	Reck, M., Popat, S., Reinmuth, N. et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann. Oncol., 25 (2014),pp. iii27-39
[43]	Rekhtman, N., Leighl, N.B., Somerfield, M.R. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline J. Oncol. Pract., 11 (2015),pp. 135-136
[44]	Rizvi, N.A., Hellmann, M.D., Snyder, A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer Science, 348 (2015),pp. 124-128
[45]	Rizvi, N.A., Mazieres, J., Planchard, D. et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial Lancet Oncol., 16 (2015),pp. 257-265
[46]	Robert, C., Karaszewska, B., Schachter, J. et al. Improved overall survival in melanoma with combined dabrafenib and trametinib N. Engl. J. Med., 372 (2015),pp. 30-39
[47]	Robertson, K.A., Nalepa, G., Yang, F.C. et al. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial Lancet Oncol., 13 (2012),pp. 1218-1224
[48]	Robinson, S.D., O'Shaughnessy, J.A., Cowey, C.L. et al. Lung Cancer, 85 (2014),pp. 326-330
[49]	Robles, A.I., Linke, S.P., Harris, C.C. The p53 network in lung carcinogenesis Oncogene, 21 (2002),pp. 6898-6907
[50]	Rudin, C.M., Hong, K., Streit, M. Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer J. Thorac. Oncol., 8 (2013),pp. e41-e42
[51]	Sanchez-Cespedes, M., Reed, A.L., Buta, M. et al. Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer Oncogene, 18 (1999),pp. 5843-5849
[52]	Schmid, S., Siano, M., Joerger, M. et al. Lung Cancer, 87 (2015),pp. 85-87
[53]	Sequist, L.V., Soria, J.C., Goldman, J.W. et al. N. Engl. J. Med., 372 (2015),pp. 1700-1709
[54]	Shackelford, D.B., Abt, E., Gerken, L. et al. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin Cancer Cell, 23 (2013),pp. 143-158
[55]	Shaw, A.T., Engelman, J.A. N. Engl. J. Med., 370 (2014),pp. 2537-2539
[56]	Shaw, A.T., Ou, S.H., Bang, Y.J. et al. N. Engl. J. Med., 371 (2014),pp. 1963-1971
[57]	Sherr, C.J. The INK4a/ARF network in tumour suppression Nat. Rev. Mol. Cell Biol., 2 (2001),pp. 731-737
[58]	Sherr, C.J., McCormick, F. The RB and p53 pathways in cancer Cancer Cell, 2 (2002),pp. 103-112
[59]	Siegel, R.L., Miller, K.D., Jemal, A. Cancer statistics, 2015 CA Cancer J. Clin., 65 (2015),pp. 5-29
[60]	Thomas, A., Liu, S.V., Subramaniam, D.S. et al. Refining the treatment of NSCLC according to histological and molecular subtypes Nat. Rev. Clin. Oncol., 12 (2015),pp. 511-526
[61]	Thress, K.S., Paweletz, C.P., Felip, E. et al. Nat. Med., 21 (2015),pp. 560-562
[62]	Topalian, S.L., Hodi, F.S., Brahmer, J.R. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N. Engl. J. Med., 366 (2012),pp. 2443-2454
[63]	Tricker, E.M., Xu, C., Uddin, S. et al. Cancer Discov., 5 (2015),pp. 960-971
[64]	Weber, J.S., D'Angelo, S.P., Minor, D. et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial Lancet Oncol., 16 (2015),pp. 375-384